Isabel Castrejón1, Maxime Dougados1, Bernard Combe1, Bruno Fautrel1, Francis Guillemin1, Theodore Pincus2. 1. From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France.I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. 2. From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France.I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. tedpincus@gmail.com.
Abstract
OBJECTIVE: To identify baseline variables that predict remission according to different criteria in rheumatoid arthritis (RA) in a comprehensive French ESPOIR early arthritis database. METHODS: Individual variables and indices at baseline were analyzed in 664 patients for capacity to predict remission either 6 or 12 months later according to 4 criteria that require a formal joint count: the American College of Rheumatology/European League Against Rheumatism Boolean criteria, the Simplified Disease Activity Index, the Clinical Disease Activity Index, and the 28-joint Disease Activity Score; and 2 remission criteria that do not require a formal joint count: the Routine Assessment of Patient Index Data 3 (RAPID3) and the RAPID3 ≤ 3 + swollen joint, using univariate and multivariate logistic regressions. RESULTS: Remission was predicted significantly 6 and/or 12 months later in 26.8%-51.4% of patients, according to all 6 criteria by younger age, low index scores, and better status for the 6/7 clinical RA core dataset measures: tender joint count, swollen joint count (SJC), physician's global estimate, patient self-report Health Assessment Questionnaire (HAQ) physical function, pain, and patient's global estimate. Remission was not predicted by the absence of "poor prognosis RA" indicators, rheumatoid factor (RF), anticitrullinated protein antibodies (ACPA), or radiographic erosions. In multivariate regressions that included only 3 variables, low HAQ function predicted remission by all criteria as effectively as SJC, erythrocyte sedimentation rate, or C-reactive protein. CONCLUSION: Younger age and 6 core dataset clinical measures, but not the absence of traditional "poor prognosis RA" indicators, RF, ACPA, or radiographic erosions, predicted remission according to 6 criteria, including 2 without a formal joint count.
OBJECTIVE: To identify baseline variables that predict remission according to different criteria in rheumatoid arthritis (RA) in a comprehensive French ESPOIR early arthritis database. METHODS: Individual variables and indices at baseline were analyzed in 664 patients for capacity to predict remission either 6 or 12 months later according to 4 criteria that require a formal joint count: the American College of Rheumatology/European League Against Rheumatism Boolean criteria, the Simplified Disease Activity Index, the Clinical Disease Activity Index, and the 28-joint Disease Activity Score; and 2 remission criteria that do not require a formal joint count: the Routine Assessment of Patient Index Data 3 (RAPID3) and the RAPID3 ≤ 3 + swollen joint, using univariate and multivariate logistic regressions. RESULTS: Remission was predicted significantly 6 and/or 12 months later in 26.8%-51.4% of patients, according to all 6 criteria by younger age, low index scores, and better status for the 6/7 clinical RA core dataset measures: tender joint count, swollen joint count (SJC), physician's global estimate, patient self-report Health Assessment Questionnaire (HAQ) physical function, pain, and patient's global estimate. Remission was not predicted by the absence of "poor prognosis RA" indicators, rheumatoid factor (RF), anticitrullinated protein antibodies (ACPA), or radiographic erosions. In multivariate regressions that included only 3 variables, low HAQ function predicted remission by all criteria as effectively as SJC, erythrocyte sedimentation rate, or C-reactive protein. CONCLUSION: Younger age and 6 core dataset clinical measures, but not the absence of traditional "poor prognosis RA" indicators, RF, ACPA, or radiographic erosions, predicted remission according to 6 criteria, including 2 without a formal joint count.
Authors: K Albrecht; A Richter; Y Meissner; D Huscher; L Baganz; K Thiele; M Schneider; A Strangfeld; A Zink Journal: Z Rheumatol Date: 2017-06 Impact factor: 1.372
Authors: Rocio V Gamboa-Cárdenas; Manuel F Ugarte-Gil; Massardo Loreto; Mónica P Sacnun; Verónica Saurit; Mario H Cardiel; Enrique R Soriano; Cecilia Pisoni; Claudio M Galarza-Maldonado; Carlos Rios; Sebastião C Radominski; Geraldo da R Castelar-Pinheiro; Washington Alves Bianchi; Simone Appenzeller; Inés Guimarães da Silveira; Cristiano A de Freitas Zerbini; Carlo V Caballero-Uribe; Adriana Rojas-Villarraga; Marlene Guibert-Toledano; Francisco Ballesteros; Rubén Montufar; Janitzia Vázquez-Mellado; Jorge Esquivel-Valerio; Ignacio García De La Torre; Leonor A Barile-Fabris; Fedra Irazoque Palezuelos; Lilia Andrade-Ortega; Pablo Monge; Raquel Teijeiro; Ángel F Achurra-Castillo; María H Esteva Spinetti; Graciela S Alarcón; Bernardo A Pons-Estel Journal: Clin Rheumatol Date: 2019-06-03 Impact factor: 2.980
Authors: Sytske Anne Bergstra; Maura C Couto; Nimmisha Govind; Arvind Chopra; Karen Salomon Escoto; Elizabeth Murphy; Tom Wj Huizinga; Cornelia F Allaart Journal: RMD Open Date: 2019-07-30